Barclays analyst Peter Lawson lowered the firm’s price target on MacroGenics (MGNX) to $3 from $8 and keeps an Overweight rating on the shares post the earnings report. The firm de-risked the model to reflect the current market environment.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX:
- MacroGenics reports Q1 EPS (65c), consensus (69c)
- MGNX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MacroGenics price target lowered to $2 from $4 at H.C. Wainwright
- MacroGenics: Hold Rating Amidst Development Halts and Financial Challenges
- MacroGenics Inc’s 2024 Earnings Call Highlights